- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.03. | Healthcare communications | ||
| 05.03. | Moderna's RSV vaccine mRESVIA granted MHRA approval to protect older adults | ||
| 05.03. | Roche's Genentech granted FDA approval for TNKase in acute ischaemic stroke | ||
| 05.03. | BeiGene's Tevimbra approved by FDA for first-line oesophageal cancer use | ||
| 05.03. | Luto expands to Switzerland with new office | ||
| 05.03. | Setting your sights - the marketing objectives that guide everything that follows | ||
| 04.03. | J&J receives three CHMP recommendations for immunology and oncology indications | ||
| 04.03. | Sobi receives NICE recommendation for Altuvoct in severe haemophilia A | ||
| 04.03. | MHRA approves Galderma's Nemluvio to treat atopic dermatitis and prurigo nodularis | ||
| 04.03. | The full potential of patient journeys in pharma | ||
| 03.03. | Rare diseases: Novartis' Fabhalta recommended by CHMP for C3 glomerulopathy | ||
| 03.03. | Rare diseases: CHMP recommends Krystal's Vyjuvek for dystrophic epidermolysis bullosa | ||
| 03.03. | Key clinical trial trends - EU vs US perspectives | ||
| 28.02. | Rare Disease Day 2025 - highlighting recent approvals in the rare disease space | ||
| 28.02. | Researchers discover previously unidentified genes linked to rare diseases | ||
| 28.02. | Defying the odds: speeding patient access to life-changing treatments in rare disease | ||
| 27.02. | Eli Lilly unveils plans to invest $27bn in four new US manufacturing sites | ||
| 27.02. | EC approves Celltrion's RoActemra biosimilar Avtozma for inflammatory diseases | ||
| 27.02. | Why local knowledge is key to global pharmacovigilance outcomes | ||
| 26.02. | Amgen's Blincyto recommended by NICE for new adult leukaemia indication | ||
| 26.02. | AstraZeneca's camizestrant shows promise in phase 3 breast cancer study | ||
| 26.02. | J&J's shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial | ||
| 26.02. | NHS England appoints Sir James Mackey as CEO | ||
| 26.02. | DE&I in clinical trials: the role of health literacy and AI | ||
| 25.02. | FDA approves Mirum's Ctexli as first treatment for rare lipid storage disease CTX |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
